Magdalena Piróg

Dr. Magdalena Piróg

Jagiellonian University, Kraków, Małopolskie, Poland
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Vascular Pharmacology
Verified
Journal Article
Closed access
ABAgata Hanna Bryk
Agata Hanna Bryk
MPMagdalena Piróg
Magdalena Piróg
KPKrzysztof Plens
Krzysztof Plens
AUAnetta Undas
Anetta Undas

1 September 2011 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
JSJakub Swadzba
Jakub Swadzba
TIT. Iwaniec
T. Iwaniec
MPMagdalena Piróg
Magdalena Piróg
BLB. DE Laat
B. DE Laat
PGP. G. DE Groot
P. G. DE Groot
JMJ. Musial
J. Musial

1 October 2017 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
MPMagdalena Piróg
Magdalena Piróg
RJRobert Jach
Robert Jach
AUAnetta Undas
Anetta Undas

31 October 2017 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
PDF file
MPMagdalena Piróg
Magdalena Piróg
RJRobert Jach
Robert Jach
OKOlga Kacalska‐Janssen
Olga Kacalska‐Janssen

1 July 2021 in Reproductive BioMedicine Online
Verified
Journal Article
Closed access
MPMagdalena Piróg
Magdalena Piróg
OKOlga Kacalska-Janssen
Olga Kacalska-Janssen
RJRobert Jach
Robert Jach
MZMichał Ząbczyk
Michał Ząbczyk
JNJoanna Natorska
Joanna Natorska

1 May 2016 in Menopause
Verified
Journal Article
Closed access
MPMagdalena Piróg
Magdalena Piróg
TMTomasz Milewicz
Tomasz Milewicz
RJRobert Jach
Robert Jach
AUAnetta Undas
Anetta Undas
Postmenopausal women are at risk of thromboembolic events. It is unclear whether menopause alters fibrin clot properties. The aim of our study was to assess the effects of menopause and hormone therapy on clot characteristics. Ex vivo plasma clot permeability, turbidity, and susceptibility to lysis were determined in 70 premenopausal and 70 postmenopausal women (a case-control study). From the postmenopausal group, 30 women were randomly assigned (1:1) to a 24-week oral or transdermal treatment with 17β-estradiol, combined with norethisterone acetate (2 mg + 1 mg/d or 0.05 mg + 5 mg/d, respectively). Compared with premenopausal women (aged 29.2 ± 2.60 y), postmenopausal women (aged 49.7 ± 3.4 y; P = 0.009) were characterized by higher fibrinogen levels (by 36.8%), lower C-reactive protein levels (by 36.9%), and lower clot permeability (by 10.5%); also after adjustment for fibrinogen (all P < 0.05), with no difference in turbidimetric or fibrinolytic variables. Estrogen plus progestogen therapy led to higher maximal absorbency of fibrin gels by 6.0% (P < 0.05), whereas all other fibrin variables remained unchanged. Compared with transdermal hormone therapy, 24-week oral therapy was associated with higher absorbency of plasma clots by 16% (P < 0.05), without any other changes in fibrin characteristics. Menopause age is associated with the formation of denser fibrin clots. Estrogen plus progestogen therapy has a minor effect on plasma fibrin properties, but leads to the formation of thicker and more branched fibrin fibers, particularly during oral administration.